News

@AJMC_Journal
ajmc.com > view > benefits-tradeoffs-of-medically-integrated-dispensing-in-oncology-care-katherine-tobon-pharmd-bcop

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP | AJMC

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP | AJMC2+ hour, 26+ min ago   (329+ words) Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP. In this clip, Katherine Tobon, PharmD, BCOP, of Moffitt Cancer Center, defines medically integrated dispensing (MID), how it is implemented…...

@AJMC_Journal
ajmc.com > view > even-after-6-years-disease-progression-impacts-survival-in-mantle-cell-lymphoma

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma | AJMC

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma | AJMC18+ hour, 57+ min ago   (367+ words) A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern. A population-based study from Sweden upends conventional thinking on when patients with mantle cell lymphoma (MCL) can…...

@AJMC_Journal
ajmc.com > view > is-less-more-after-thrombolysis-debating-intensive-stroke-monitoring-at-isc-2026

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026 | AJMC

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026 | AJMC21+ hour, 7+ min ago   (805+ words) In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care. As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive monitoring protocols…...

@AJMC_Journal
ajmc.com > view > exploring-identity-appearance-experiences-among-patients-with-alopecia

Exploring Identity, Appearance Experiences Among Patients With Alopecia | AJMC

Exploring Identity, Appearance Experiences Among Patients With Alopecia | AJMC1+ day, 1+ hour ago   (259+ words) Alopecia profoundly disrupts identity, emotional wellbeing, and social life, with many people struggling due to stigma, concealment pressures, and unmet psychological support needs. The review synthesized data from 22 qualitative studies representing experiences of nearly 1,000 people across the globe with alopecia,…...

@AJMC_Journal
ajmc.com > view > potential-predictor-of-treatment-response-in-chronic-spontaneous-urticaria-identified

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified | AJMC

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified | AJMC1+ day, 1+ hour ago   (343+ words) Findings from a new study suggest that serum haptoglobin (HP) may serve as a useful prognostic biomarker for predicting treatment response and complete disease control in chronic spontaneous urticaria (CSU).1 The researchers highlighted the potential of their findings, as identifying…...

@AJMC_Journal
ajmc.com > view > stroke-subtype-does-not-affect-efficacy-of-asundexian-for-second-stroke-prevention

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention | AJMC

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention | AJMC1+ day, 4+ hour ago   (549+ words) The overall OCEANIC-STROKE results made waves at ISC 2026, and the prespecified secondary analysis focused on qualifying ischemic stroke subtypes.1 "As we know, a noncardioembolic ischemic stroke is an umbrella term that has heterogeneous ischemic stroke etiologies within it," Shoamanesh said....

@AJMC_Journal
ajmc.com > view > linking-community-screening-programs-to-cancer-centers-boosts-trial-diversity-susan-vadaparampil-phd-mph

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH | AJMC

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH | AJMC1+ day, 7+ hour ago   (305+ words) Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help. There are notable disparities in cancer incidence and outcomes by race, ethnicity, age, and location, according…...

@AJMC_Journal
ajmc.com > view > 5-things-to-know-about-the-oral-glp-1-era

5 Things to Know About the Oral GLP-1 Era | AJMC

5 Things to Know About the Oral GLP-1 Era | AJMC1+ day, 7+ hour ago   (357+ words) Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist. The FDA cleared the Wegovy pill (Novo Nordisk), a once-daily oral semaglutide 25-mg formulation for chronic weight management, based on 64-week phase…...

@AJMC_Journal
ajmc.com > view > how-do-glp-1-agonists-fit-into-stroke-care-

How Do GLP-1 Agonists Fit Into Stroke Care? | AJMC

How Do GLP-1 Agonists Fit Into Stroke Care? | AJMC1+ day, 7+ hour ago   (717+ words) Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms. Samarth Shah, PharmD, BCPS, clinical pharmacy specialist at the Hospital of the University of Pennsylvania, first…...

@AJMC_Journal
ajmc.com > view > aligning-treatment-goals-in-iga-nephropathy-applying-kdigo-s-dual-pathway-framework-to-clinical-decision-making

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making | AJMC

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making | AJMC1+ day, 11+ hour ago   (852+ words) Dr. Luis Sanchez Russo highlighted that IgA nephropathy (IgAN) management has evolved beyond a singular focus on slowing kidney function decline to a more comprehensive, mechanism-driven approach. Today, the primary treatment goals in IgAN center on reducing proteinuria, preserving long-term…...